Characterization of antigen-presenting dendritic cells in the peripheral blood and colonic mucosa of patients with ulcerative colitis

Ikeda, Yoshio; Akbar, Fazle; Matsui, Hidetaka; Onji, Morikazu

doi:10.1097/00042737-200107000-00013

Cited by 53 publications

(38 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…28 In the PB of patients with IBD, increased numbers of DC expressing CD83 and CD86 have been found and matured DC generated from peripheral blood monocytes of IBD patients show raised immune-stimulating abilities when compared with those of healthy volunteers. 39 Activated DC found at the sites of inflammation in murine models of colitis might contribute to the pathogenesis, 11 and there is increasing evidence that mucosal DC accumulated within inflamed tissue might also play a role in human IBD. 16,40 Regarding DC in the peripheral blood of IBD patients, conflicting results have been reported.…”

Section: Discussionmentioning

confidence: 99%

Dendritic cells from human mesenteric lymph nodes in inflammatory and non‐inflammatory bowel diseases: subsets and function of plasmacytoid dendritic cells

et al. 2013

View full text Add to dashboard Cite

SummaryPlasmacytoid dendritic cells (pDC) in mesenteric lymph nodes (MLN) may be important regulators of both inflammatory and non-inflammatory mucosal immune responses but human studies are rare. Here we compare pDC from human MLN and peripheral blood (PB) by phenotype and function. MLN from patients with or without inflammatory bowel disease (IBD) undergoing colon surgery and PB from patients with IBD and from controls were used to isolate mononuclear cells. The pDC were analysed by flow cytometry for the expression of CD40, CD80, CD83, CD86, CCR6, CCR7, CX3CR1, CD103 and HLA-DR. Purified pDC from MLN and PB were stimulated with staphylococcus enterotoxin B (SEB), CpG-A, interleukin-3 (IL-3), SEB + IL-3, CpG-A + IL-3 or left unstimulated, and cultured alone or with purified allogeneic CD4 + CD45RA + HLA-DR-T cells. Subsequently, concentrations of IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-17, interferon-a (IFN-a), IFN-c and tumour necrosis factor-a (TNF-a) in culture supernatants were determined by multiplex bead array. The PB pDC from IBD patients exhibited an activated and matured phenotype whereas MLN pDC and control PB pDC were less activated. CpG-A and CpG-A + IL-3-stimulated MLN pDC secreted less IL-6 and TNF-a compared with PB pDC from controls. Compared with co-cultures of naive CD4 T cells with PB pDC, co-cultures with MLN pDC contained more IL-2, IL-10 and IFN-c when stimulated with SEB and SEB + IL-3, and less IFN-a when stimulated with CpG-A. MLN pDC differ phenotypically from PB pDC and their pattern of cytokine secretion and may contribute to specific outcomes of mucosal immune reactions.

show abstract

Section: Discussionmentioning

confidence: 99%

Dendritic cells from human mesenteric lymph nodes in inflammatory and non‐inflammatory bowel diseases: subsets and function of plasmacytoid dendritic cells

et al. 2013

View full text Add to dashboard Cite

show abstract

“…10,2003 TYPHOID VACCINE RESPONSE IN PATIENTS WITH COLECTOMIES 429 the distal ileum. The impaired T-and B-cell responses observed in the circulation of patients who have undergone colectomies suggest that the terminal ileum and colon may be of importance in the induction of systemic immune responses to the Ty21a vaccine.…”

Section: Discussionmentioning

confidence: 99%

T- and B-Cell Immune Responses of Patients Who Had Undergone Colectomies to Oral Administration of Salmonella enterica Serovar Typhi Ty21a Vaccine

Kilhamn

Lundin²,

Brevinge

et al. 2003

Clin Vaccine Immunol

View full text Add to dashboard Cite

The capacity of an oral live attenuated Salmonella enterica serovar Typhi Ty21a vaccine to induce immune responses in patients who had undergone colectomies because of ulcerative colitis was evaluated, and these responses were compared with those of healthy volunteers. Purified CD4 ؉ and CD8 ؉ T cells from peripheral blood were stimulated in vitro by using the heat-killed Ty21a vaccine strain, and the proliferation and gamma interferon (IFN-␥) production were measured before and 7 or 8 days after vaccination. Salmonella-specific immunoglobulin A (IgA) and IgG antibody responses in serum along with IgA antibody responses in ileostomy fluids from the patients who had undergone colectomies were also evaluated. Three doses of vaccine given 2 days apart failed to induce proliferative T-cell responses in all the six patients who had undergone colectomies, and increases in IFN-␥ production were found only among the CD8 ؉ cells from three of the patients. In contrast, both proliferative responses and increased IFN-␥ production were observed among CD4 ؉ and CD8

show abstract

“…The number of DCs expressing the maturation markers CD80, CD83, CD86 and CD40 is elevated in CD and UC [102][103][104][105]. DCs express also higher levels of TLR2 and TLR4 [102] and accordingly, show exaggerated response to LPS in IBD [106].…”

Section: Immune Dysregulationmentioning

confidence: 99%

Gut Inflammation: Current Update on Pathophysiology, Molecular Mechanism and Pharmacological Treatment Modalities

Gyires¹,

Tóth²,

Zádori

2014

CPD

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a chronic and relapsing inflammatory condition of the gastrointestinal tract. The two main forms of IBD are Crohn's disease and ulcerative colitis. According to the recent concept the disease is caused by a combination of factors, including genetics, immune dysregulation, barrier dysfunction and the change in microbial flora. Environmental factors, such as changes in diet, antibiotic use, smoking or improved domestic hygiene (e.g. eradication of intestinal helminths) probably contribute to the development and increased prevalence of IBD. Dysregulation of mucosal immunity in IBD causes an overproduction of inflammatory cytokines which resulted in uncontrolled intestinal inflammation. Based on extensive research over the last decade, besides the conventional therapy, there are several novel pathways and specific targets, on which focus new therapeutics. New therapeutics aim 1./ to correct genetic susceptibility by stimulating NOD2 expression, TLR3 signaling or inhibition of TLR4 pathway, 2./ to restore the immune dysregulation by inhibition of pro-inflammatory cytokines (TNF-, IL-6, IL-13, IL-17, IL-18, IL-21), Th1 polarisation (IL-2, IL-12, IL-23, IFN-), T-cell activation, leukocyte adhesion, as well as by immunostimulation (GM-CSF, G-CSF) and anti-inflammatory cytokines (IL-10, IL-11, IFN--1a), 3./ to restore mucosal barrier function and stimulate mucosal healing by different growth factors, such as GH, EGF, KGF, TGF-, VEGF, 4./ to restore the normal bacterial flora by antibiotics, probiotics. However, in spite of these numerous potential targets, the true value and clinical significance of most of the new biologics and molecules are not clear yet.

show abstract

Characterization of antigen-presenting dendritic cells in the peripheral blood and colonic mucosa of patients with ulcerative colitis

Cited by 53 publications

References 21 publications

Dendritic cells from human mesenteric lymph nodes in inflammatory and non‐inflammatory bowel diseases: subsets and function of plasmacytoid dendritic cells

Dendritic cells from human mesenteric lymph nodes in inflammatory and non‐inflammatory bowel diseases: subsets and function of plasmacytoid dendritic cells

T- and B-Cell Immune Responses of Patients Who Had Undergone Colectomies to Oral Administration of Salmonella enterica Serovar Typhi Ty21a Vaccine

Gut Inflammation: Current Update on Pathophysiology, Molecular Mechanism and Pharmacological Treatment Modalities

Contact Info

Product

Resources

About